{"id":71847,"date":"2026-08-06T14:57:30","date_gmt":"2026-08-06T06:57:30","guid":{"rendered":"https:\/\/flcube.com\/?p=71847"},"modified":"2026-08-06T14:57:31","modified_gmt":"2026-08-06T06:57:31","slug":"syndax-terminates-entinostat-license-agreement-with-eoc-hk-ending-jingzhuda-commercial-rights-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71847","title":{"rendered":"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Syndax Pharmaceuticals, Inc.<\/strong> announced the <strong>termination of its license agreement<\/strong> with <strong>EOC Pharma (Hong Kong) Limited (&#8220;EOC HK&#8221;)<\/strong> regarding <strong>entinostat<\/strong> (brand name: <strong>Jingzhuda<\/strong>), an <strong>oral histone deacetylase (HDAC) inhibitor<\/strong> approved in China in April 2024 for <strong>HR-positive, HER2-negative breast cancer<\/strong>. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate <strong>sub-license agreements<\/strong> with <strong>Taizhou EOC Pharma<\/strong> and <strong>Suzhou Eddingpharm<\/strong>, disrupting the commercial structure for Jingzhuda in mainland China.<\/p>\n\n\n\n<h2 id=\"h-license-agreement-termination-summary\" class=\"wp-block-heading\">License Agreement Termination Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Original Agreement<\/strong><\/td><td>April 2013 license between Syndax and EOC HK<\/td><\/tr><tr><td><strong>Terminated Rights<\/strong><\/td><td>Patents, intellectual property, and sub-licensing rights for entinostat<\/td><\/tr><tr><td><strong>Chinese Approval<\/strong><\/td><td>April 2024 for HR+\/HER2- breast cancer (combination with aromatase inhibitors)<\/td><\/tr><tr><td><strong>Sub-License Chain<\/strong><\/td><td>EOC HK \u2192 Taizhou EOC (2018) \u2192 Suzhou Eddingpharm (2023)<\/td><\/tr><tr><td><strong>Current Status<\/strong><\/td><td>All license and sub-license agreements terminated<\/td><\/tr><tr><td><strong>Commercial Impact<\/strong><\/td><td>Immediate cessation of Jingzhuda commercialization rights in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-regulatory-status\" class=\"wp-block-heading\">Product Profile &amp; Regulatory Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: <strong>Oral histone deacetylase (HDAC) inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Brand Name<\/strong>: <strong>Jingzhuda<\/strong> (China market)<\/li>\n\n\n\n<li><strong>Indication<\/strong>: <strong>Hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer<\/strong><\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Patients who have <strong>relapsed or progressed on prior endocrine therapy<\/strong><\/li>\n\n\n\n<li><strong>Approval Date<\/strong>: <strong>April 2024<\/strong> by Chinese regulatory authorities<\/li>\n\n\n\n<li><strong>Therapeutic Significance<\/strong>: Addresses significant unmet need in endocrine-resistant breast cancer<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-licensing-structure-amp-termination-cascade\" class=\"wp-block-heading\">Licensing Structure &amp; Termination Cascade<\/h2>\n\n\n\n<h3 id=\"h-original-2013-agreement\" class=\"wp-block-heading\">Original 2013 Agreement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Parties<\/strong>: Syndax Pharmaceuticals (licensor) and EOC HK (licensee)<\/li>\n\n\n\n<li><strong>Rights Granted<\/strong>: Exclusive rights to relevant patents, intellectual property, and sub-licensing authority for entinostat<\/li>\n\n\n\n<li><strong>Territory<\/strong>: Presumably included mainland China and potentially broader Asian markets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-sub-license-chain-2018-2023\" class=\"wp-block-heading\">Sub-License Chain (2018-2023)<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>2018<\/strong>: EOC HK sub-licensed <strong>mainland China rights<\/strong> to <strong>Taizhou EOC Pharma Co., Ltd.<\/strong><\/li>\n\n\n\n<li><strong>2023<\/strong>: Taizhou EOC further licensed <strong>Suzhou Eddingpharm Co., Ltd.<\/strong> for commercialization of entinostat in <strong>human cancers and companion diagnostic testing<\/strong><\/li>\n<\/ol>\n\n\n\n<h3 id=\"h-termination-impact\" class=\"wp-block-heading\">Termination Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EOC HK<\/strong>: No longer holds any rights to entinostat<\/li>\n\n\n\n<li><strong>Taizhou EOC<\/strong>: Sub-license automatically terminated due to upstream termination<\/li>\n\n\n\n<li><strong>Suzhou Eddingpharm<\/strong>: Commercialization rights revoked, halting marketing activities<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Immediate disruption to Jingzhuda availability for Chinese patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-syndax-pharmaceuticals\" class=\"wp-block-heading\">For Syndax Pharmaceuticals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Direct Control<\/strong>: Regains full control over entinostat commercialization strategy in China<\/li>\n\n\n\n<li><strong>Alternative Partnerships<\/strong>: May seek new commercial partner with stronger execution capabilities<\/li>\n\n\n\n<li><strong>Revenue Impact<\/strong>: Loss of royalty stream from existing commercialization, but potential for improved terms with new partner<\/li>\n\n\n\n<li><strong>Strategic Reassessment<\/strong>: Opportunity to restructure China strategy following recent approval<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-chinese-pharmaceutical-companies\" class=\"wp-block-heading\">For Chinese Pharmaceutical Companies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EOC HK\/Taizhou EOC<\/strong>: Significant setback to oncology portfolio and revenue expectations<\/li>\n\n\n\n<li><strong>Suzhou Eddingpharm<\/strong>: Loss of recently launched commercial product and associated investment<\/li>\n\n\n\n<li><strong>Market Disruption<\/strong>: Chinese patients may face temporary access issues for approved indication<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-chinese-breast-cancer-market\" class=\"wp-block-heading\">For Chinese Breast Cancer Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Continuity<\/strong>: Potential interruption in access to approved HDAC inhibitor combination therapy<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Creates opportunity for alternative HDAC inhibitors or competing mechanisms<\/li>\n\n\n\n<li><strong>Regulatory Precedent<\/strong>: Highlights risks of complex multi-tier licensing structures in Chinese pharmaceutical market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The termination represents a significant disruption to the commercial ecosystem established for entinostat in China and underscores the complexities of international pharmaceutical licensing in emerging markets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding business relationships, commercial strategies, and market impacts. Actual outcomes may differ materially due to regulatory decisions, competitive dynamics, patient access considerations, and strategic realignments by involved parties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080502026_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080502026_c.\"><\/object><a id=\"wp-block-file--media-6581752c-f61f-4e70-bf4c-e11b94d64bb4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080502026_c.pdf\">2026080502026_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080502026_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6581752c-f61f-4e70-bf4c-e11b94d64bb4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[834,4879],"class_list":["post-71847","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eoc-pharma","tag-syndax-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (&quot;EOC HK&quot;) regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71847\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China\" \/>\n<meta property=\"og:description\" content=\"Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (&quot;EOC HK&quot;) regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71847\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-06T06:57:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-06T06:57:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71847#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71847\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China\",\"datePublished\":\"2026-08-06T06:57:30+00:00\",\"dateModified\":\"2026-08-06T06:57:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71847\"},\"wordCount\":524,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"EOC Pharma\",\"Syndax Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71847#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71847\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71847\",\"name\":\"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-06T06:57:30+00:00\",\"dateModified\":\"2026-08-06T06:57:31+00:00\",\"description\":\"Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (\\\"EOC HK\\\") regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71847#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71847\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71847#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China - Insight, China&#039;s Pharmaceutical Industry","description":"Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (\"EOC HK\") regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71847","og_locale":"en_US","og_type":"article","og_title":"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China","og_description":"Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (\"EOC HK\") regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.","og_url":"https:\/\/flcube.com\/?p=71847","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-06T06:57:30+00:00","article_modified_time":"2026-08-06T06:57:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71847#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71847"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China","datePublished":"2026-08-06T06:57:30+00:00","dateModified":"2026-08-06T06:57:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71847"},"wordCount":524,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["EOC Pharma","Syndax Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71847#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71847","url":"https:\/\/flcube.com\/?p=71847","name":"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-06T06:57:30+00:00","dateModified":"2026-08-06T06:57:31+00:00","description":"Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong) Limited (\"EOC HK\") regarding entinostat (brand name: Jingzhuda), an oral histone deacetylase (HDAC) inhibitor approved in China in April 2024 for HR-positive, HER2-negative breast cancer. The termination, effective immediately, revokes all rights previously granted to EOC HK and cascades to terminate sub-license agreements with Taizhou EOC Pharma and Suzhou Eddingpharm, disrupting the commercial structure for Jingzhuda in mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71847#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71847"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71847#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71847"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71847\/revisions"}],"predecessor-version":[{"id":71850,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71847\/revisions\/71850"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}